Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts
- 1 August 1996
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (4), 537-545
- https://doi.org/10.1038/bjc.1996.398
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumorsCancer Chemotherapy and Pharmacology, 1995
- Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical TrialsJNCI Journal of the National Cancer Institute, 1994
- Effects of CPT‐11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno‐transplanted neuroblastomaMedical and Pediatric Oncology, 1994
- Mechanisms of Topoisomerase I Inhibition by Anticancer DrugsPublished by Elsevier ,1994
- Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumoursNature, 1992
- P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for NeuroblastomaNew England Journal of Medicine, 1991
- Stability of phenotypic and genotypic traits during the establishment of a human neuroblastoma cell line, IGR-N-835International Journal of Cancer, 1989
- Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1Cancer, 1989
- Preclinical phase II studies in human tumor lines: A European multicenter studyEuropean Journal of Cancer and Clinical Oncology, 1988
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984